Aravive Inc Revenue Growth Rates (ARAV), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Aravive Inc   (NASDAQ: ARAV)
 

ARAV's Revenue Growth by Quarter and Year

Aravive Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ARAV Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
4th Quarter December -
3rd Quarter September 2.76
2nd Quarter June 1.27
1st Quarter March 1.49
FY 5.52

ARAVs Annual Revenue
Aravive Inc 's Revenue in the fiscal year 2022 $ 9.14 millions
Aravive Inc 's Revenue in the fiscal year 2021 $ 7.44 millions
Aravive Inc 's Revenue in the fiscal year 2020 $ 5.69 millions
Aravive Inc 's Revenue in the fiscal year 2019 $ 4.75 millions
Aravive Inc 's Revenue in the fiscal year 2018 $ 1.37 millions




ARAV Revenue third quarter 2023 Y/Y Growth Comment
Aravive Inc reported fall in Revenue in the third quarter 2023 by -44.44% to $ 2.76 millions, from the same quarter in 2022.
The drop in the third quarter 2023 Aravive Inc 's Revenue compares unfavorably to the Company's average Revenue growth of 1.15%.

Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 207 other companies have achieved higher Revenue growth. While Aravive Inc ' s Revenue drop of -44.44% ranks overall at the positon no. 3678 in the third quarter 2023.


ARAV Revenue ( Y/Y Growth %) 2023
 2022 2021 2020
4th Quarter December - 48.48 % -82.6 % -
3rd Quarter September -44.44 % 105.81 % - -
2nd Quarter June -21.6 % -57.26 % - -
1st Quarter March 36.7 % 319.23 % - -
FY   - 22.68 % 30.93 % -

Financial Statements
Aravive Inc 's third quarter 2023 Revenue $ 2.76 millions ARAV's Income Statement
Aravive Inc 's third quarter 2022 Revenue $ 4.96 millions Quarterly ARAV's Income Statement


ARAV Revenue (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
4th Quarter December - -70.36 % -58.92 % -
3rd Quarter September 117.01 % 206.17 % -36.41 % -
2nd Quarter June -14.77 % 48.62 % 1357.69 % -
1st Quarter March 1.36 % 10.1 % -95.43 % -
FY (Year on Year)   - 22.68 % 30.93 % -


Back to ARAV Growth rate Comparisons >> Back to ARAV Growth rate Comparisons >>


Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #208
Healthcare Sector #548
Overall #3678

Revenue Y/Y Growth Statistics
High Average Low
326.56 % 1.15 % -100 %
(Mar 31 2022)   (Jun 30 2020)
Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #208
Healthcare Sector #548
Overall #3678
Revenue Y/Y Growth Statistics
High Average Low
326.56 % 1.15 % -100 %
(Mar 31 2022)   (Jun 30 2020)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Aravive Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1380.08 % 97.65 % -100 %
(Jun 30 2021)  


ARAV's III. Quarter Q/Q Revenue Comment
Aravive Inc achieved in the III. Quarter 2023 above company average sequential Revenue doubling of 117.01%, to $ 2.76 millions, from $1.27 millions in the second quarter.

Within Major Pharmaceutical Preparations industry 31 other companies have achieved higher Revenue quarter on quarter growth. While Aravive Inc 's Revenue growth quarter on quarter, overall rank is 121.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #32
Healthcare Sector #59
Overall #121
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #32
Healthcare Sector #59
Overall #121
Revenue Q/Q Growth Statistics
High Average Low
1380.08 % 97.65 % -100 %
(Jun 30 2021)  


ARAV's III. Quarter Q/Q Revenue Comment
Aravive Inc achieved in the III. Quarter 2023 above company average sequential Revenue doubling of 117.01%, to $ 2.76 millions, from $1.27 millions in the second quarter.

Within Major Pharmaceutical Preparations industry 31 other companies have achieved higher Revenue quarter on quarter growth. While Aravive Inc 's Revenue growth quarter on quarter, overall rank is 121.


Aravive Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)		 12 Months Ending
(Mar 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Sep 30 2022)
Cumulative Revenue 12 Months Ending $ 6.99 $ 9.20 $ 9.54 $ 9.14 $ 8.65
Y / Y Revenue Growth (TTM) -19.11 % 50.64 % 15.2 % 22.78 % -28.78 %
Year on Year Revenue Growth Overall Ranking # 2425 # 3138 # 2220 # 2273 # 3350
Seqeuential Revenue Change (TTM) -23.93 % -3.58 % 4.37 % 5.65 % 41.68 %
Seq. Revenue Growth (TTM) Overall Ranking # 279 # 3114 # 1671 # 2313 # 3476


Cumulative Revenue growth Comment
For the 12 months ended Sep 30 2023 Aravive Inc reported a fall in Revenue by -19.11% year on year, to $7 millions, compare to the 50.64% growth at Jun 30 2023.

In the Healthcare sector 335 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 2425, from total ranking in previous quarter at 3138.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 49
Healthcare Sector # 336
Overall # 2425

Revenue TTM Y/Y Growth Statistics
High Average Low
50.64 %
 8.14 %
-28.78 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 49
Sector # 93
S&P 500 # 279
Cumulative Revenue growth Comment
For the 12 months ended Sep 30 2023 Aravive Inc reported a fall in Revenue by -19.11% year on year, to $7 millions, compare to the 50.64% growth at Jun 30 2023.

In the Healthcare sector 335 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 2425, from total ranking in previous quarter at 3138.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 49
Healthcare Sector # 336
Overall # 2425

Revenue TTM Y/Y Growth Statistics
High Average Low
50.64 %
8.14 %
-28.78 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 49
Sector # 93
S&P 500 # 279




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ARAV's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2023
Adaptimmune Therapeutics Plc-0.16%$ -0.164 millions
Procyon Corporation-0.22%$ -0.221 millions
Amedisys Inc-0.31%$ -0.314 millions
Karyopharm Therapeutics Inc -0.38%$ -0.376 millions
Vycor Medical Inc -0.44%$ -0.442 millions
Establishment Labs Holdings Inc -0.50%$ -0.505 millions
Opko Health Inc -0.64%$ -0.639 millions
Integra Lifesciences Holdings Corp-0.72%$ -0.719 millions
Healthcare Services Group Inc -0.75%$ -0.748 millions
Phibro Animal Health Corporation-0.77%$ -0.772 millions
Hologic Inc-0.81%$ -0.808 millions
Bionexus Gene Lab Corp -0.83%$ -0.831 millions
Bellicum Pharmaceuticals Inc -0.89%$ -0.890 millions
Prestige Consumer Healthcare Inc -1.12%$ -1.125 millions
Sharecare Inc -1.13%$ -1.127 millions
Lifevantage Corp-1.14%$ -1.140 millions
Organon and Co -1.17%$ -1.171 millions
Optinose Inc -1.27%$ -1.270 millions
Baxter International Inc -1.72%$ -1.723 millions
Puma Biotechnology Inc -1.73%$ -1.727 millions
Blueprint Medicines Corporation-1.76%$ -1.763 millions
Standard Biotools Inc -1.92%$ -1.918 millions
Pacira Biosciences inc -2.11%$ -2.114 millions
Bristol myers Squibb Company-2.25%$ -2.246 millions
Aurinia Pharmaceuticals Inc -2.27%$ -2.266 millions
Abbott Laboratories-2.56%$ -2.565 millions
Enhabit Inc -2.79%$ -2.785 millions
Novocure Limited-2.81%$ -2.807 millions
Uniqure N v -2.90%$ -2.899 millions
Vaso Corporation-2.92%$ -2.925 millions


About Aravive Inc Revenue Growth Rates (ARAV), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Aravive Inc (CIK 1513818).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001437749-23-031247
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Aravive Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.